• For investors wondering whether IDEXX Laboratories at around US$557 per share offers fair value or is asking too much for its future potential, this article breaks down what the current price may be implying about the stock.
• The stock is up 2.0% over the past week, although it is down 1.5% over the last month and down 16.8% year to date, with a 7.9% return over the past year and 19.5% over three years but just 1.2% over five years.
• Recent coverage has focused on IDEXX Laboratories as a key player in veterinary diagnostics and animal health solutions, with attention on how its business model fits into long term trends in pet care and diagnostics. This context has kept investors focused on whether the current share price fairly reflects those structural themes or builds in too much optimism.
• On Simply Wall St's valuation checks, IDEXX Laboratories scores 1 out of 6, as shown in the valuation score. The next sections will compare different valuation approaches and then finish with a broader way to think about what the current price really means.

IDEXX Laboratories scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: IDEXX Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today to estimate what the business might be worth right now.

For IDEXX Laboratories, the model uses a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $1.06b. Analyst forecasts and subsequent extrapolations by Simply Wall St point to free cash flow of $1.16b in 2026 and $1.88b by 2030, with further estimates out to 2035 included in the calculation.

When all of those projected cash flows are discounted back to today, the DCF model produces an estimated intrinsic value of about $553.42 per share. Against a current share price of around $557, the model suggests the stock is about 0.7% overvalued, which is effectively a tight range around the calculated fair value.

Result: ABOUT RIGHT

IDEXX Laboratories is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: IDEXX Laboratories Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand for how much you are paying for each dollar of current earnings, which makes it a common starting point when you compare stocks.

What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings appear. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower multiple.

IDEXX Laboratories currently trades on a P/E of about 40.1x. That sits above the Medical Equipment industry average P/E of 24.4x and also above the peer group average of 26.7x, so the stock is priced at a premium on simple comparisons.

Simply Wall St’s Fair Ratio for IDEXX Laboratories is 29.3x. This is a proprietary estimate of what the P/E might be, given factors such as earnings growth, profit margins, industry, market cap and key risks. Because it adjusts for these fundamentals, the Fair Ratio can be more informative than a basic industry or peer average.

Comparing the current P/E of 40.1x with the Fair Ratio of 29.3x suggests the stock is trading above that fair range.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your IDEXX Laboratories Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St let you attach a clear story about IDEXX Laboratories to the numbers by linking your view of its business drivers to a specific forecast and Fair Value, then comparing that Fair Value with the live share price to decide whether the stock looks expensive or cheap for your scenario.

A Narrative is simply your structured perspective. For example, one investor might lean toward the more cautious US$470 view, stressing risks like slower pet diagnostics adoption and margin pressure. Another investor might align with the optimistic US$823 view, focusing on recurring diagnostics, software and Cancer Dx potential. Both investors can express these views inside the Community page as easy to use Narratives that stay updated as new earnings or news arrive and automatically refresh the Fair Value so you can reassess your buy or sell timing without rebuilding a model from scratch.

For IDEXX Laboratories however we will make it really easy for you with previews of two leading IDEXX Laboratories Narratives:

Fair value in this Narrative: about US$750.23 per share

Implied discount to that fair value at the recent US$557.21 share price: around 25.7% lower than the Narrative fair value

Revenue growth used in this Narrative: 9.01% a year

• Focuses on expansion in new diagnostic platforms and international markets supporting recurring revenue and margins, with a growing and sticky installed base.
• Builds in analyst assumptions for revenue, margin and earnings per share out to 2028, plus a premium future P/E of 50.1x and a 7.7% discount rate.
• Flags risks around slower U.S. clinical visit trends, international adoption, reliance on new instrument placements, competition and pricing pressure.

Fair value in this Narrative: about US$530.21 per share

Implied premium to that fair value at the recent US$557.21 share price: around 5.1% above the Narrative fair value

Revenue growth used in this Narrative: 7.33% a year

• Starts from a more cautious view that demographic shifts, weaker clinic visits and higher price sensitivity could weigh on demand for premium diagnostics over time.
• Builds in lower revenue growth expectations, a future P/E of 34.2x and a 7.6% discount rate, which together pull the fair value closer to the bearish analyst cohort.
• Accepts that product development, international growth, software adoption and high retention could all challenge this cautious stance if they stay strong.

Both Narratives use the same share price but very different assumptions about revenue growth, future margins and what multiple the stock might trade on, which is why they land at such different fair values. The useful takeaway for you is not which one is right, but which set of assumptions feels closer to how you think IDEXX Laboratories will actually perform over the next few years.

Do you think there's more to the story for IDEXX Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.